RXi Pharmaceuticals has posted results from its second placebo-controlled Phase I study with RXI‑109, an sd-rxRNA compound that targets Connective Tissue Growth Factor (CTGF), and is being developed for the treatment of abnormal dermal scars such as hypertrophic scars and keloids in conjunction with scar revision surgery. In this study, subjects received small skin incisions in their abdomen and were treated with three intradermal doses of RXI‑109 during a two-week period. The dose escalating p...